Everything below concerns acylated peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
According to Fritz, China has expanded its cyber capabilities and military technology by acquiring foreign military technology. Fritz states that the Chinese government uses "new space-based surveillance and intelligence gathering systems, Anti-satellite weapon, anti-radar, infrared decoys, and false target generators" to assist in this quest, and that they support their "Informatisation" of their military through "increased education of soldiers in cyber warfare; improving the information network for military training, and has built more virtual laboratories, digital libraries and digital campuses." Through this informatisation, they hope to prepare their forces to engage in a different kind of warfare, against technically capable adversaries. Foreign Policy magazine put the size of China's "hacker army" at anywhere from 50,000 to 100,000 individuals. Diplomatic cables highlight US concerns that China is using access to Microsoft source code and 'harvesting the talents of its private sector' to boost its offensive and defensive capabilities. While China continues to be held responsible for a string of cyber-attacks on a number of public and private institutions in the United States, India, Russia, Canada, and France, the Chinese government denies any involvement in cyber-spying campaigns. The administration maintains the position that China is also victim to an increasing number of cyber-attacks. Most reports about China's cyber warfare capabilities have yet to be confirmed by the Chinese government.
=== Ca–Ce === David S. Cafiso (b. 1952). American biochemist at the University of Virginia, with research focusing on membranes and membrane proteins. Graham Cairns-Smith FRSE (1931–2016) Scottish organic chemist and molecular biologist at the University of Glasgow. John Cairns FRS (1922–2018) was a British physician and molecular biologist at the Harvard School of Public Health. T. Colin Campbell (b. 1934). American biochemist at Cornell University, specializing in the effect of nutrition on long-term health. David E. Cane (b. 1944). American biological chemist at Brown University, recognized for his work on the biosynthesis of natural products, particularly terpenoids and polyketides. Lewis C. Cantley (b. 1949). American cell biologist and biochemist at Harvard Medical School, who has made significant advances to the understanding of cancer metabolism. Member Natl. Acad. Sci. USA. Charles Cantor (b. 1942). American biophysicist at Boston University, he developed the method of pulse field gel electrophoresis, and was formerly Director of the Human Genome Project. He is known also for his book series Biophysical Chemistry with Paul Schimmel John Carbon (PhD 1955). American cellular biologist at UC Santa Barbara, known for development of techniques for making genome libraries. Member Natl. Acad. Sci. USA. María Luz Cárdenas (b. 1944). French biochemist of Chilean origin at the CNRS, Marseille, known for work on mammalian hexokinases. H. E. Carter (1910–2007). American biochemist, at the University of Illinois, known for determining the structure of threonine. Member Natl.
Skeletons excavated from the Coburn Street Burial Ground (1750 to 1827 CE) in Cape Town, South Africa, were analyzed using stable isotope data in order to determine geographical histories and life histories. The people buried in this cemetery were assumed to be slaves and members of the underclass based on the informal nature of the cemetery; biomechanical stress analysis and stable isotope analysis, combined with other archaeological data, seem to support this supposition. Based on stable isotope levels, one study reported that eight Cobern Street Burial Ground individuals consumed a diet based on C4 (tropical) plants in childhood, then consumed more C3 plants, which were more common there later in their lives. Six of these individuals had dental modifications similar to those carried out by peoples inhabiting tropical areas known to be targeted by slavers who brought enslaved individuals from other parts of Africa to the colony. Based on this evidence, it was argued that these individuals represent enslaved persons from areas of Africa where C4 plants were consumed and who were brought to the Cape as laborers. These individuals were not assigned to a specific ethnicity, but similar dental modifications are carried out by the Makua, Yao, and Marav peoples. Four individuals were buried with no grave goods, in accordance with Muslim tradition, facing Signal Hill, which is a point of significance for local Muslims.
Sources: en.wikipedia.org
== Use as a watermark == In 2010, when Craig Venter unveiled the first fully functioning, reproducing cell controlled by synthetic DNA he described how his team used frequent stop codons to create watermarks in RNA and DNA to help confirm the results were indeed synthetic (and not contaminated or otherwise), using it to encode authors' names and website addresses.
For example, capillary electrophoresis or liquid chromatography could be used if the analyte can be ionized and has a high vapor pressure, but it is also soluble in polar solvents. On the other hand, gas chromatography is the best way to test a substance that is stable at high temperatures but has a low vapor pressure. When compared to gas or liquid chromatography, supercritical fluid chromatography is a better way to measure chiral inversion because it uses mass spectrometers and a green method.
A natriuretic peptide is a hormone molecule that plays a crucial role in the regulation of the cardiovascular system. These hormones were first discovered in the 1980s and were found to have very strong diuretic, natriuretic, and vasodilatory effects. There are three main types of natriuretic peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Two minor hormones include urodilatin (URO) which is processed in the kidney and encoded by the same gene as ANP, and dendroaspis NP (DNP) that was discovered through isolation of the venom from the green mamba snake. Since they are activated during heart failure, they are important for the protection of the heart and its tissues. Additionally, there are three natriuretic peptide receptors: natriuretic peptide receptor A (NPR-A), Natriuretic Peptide Receptor-B (NPR-B), and Natriuretic Peptide Receptor-C (NPR-C). NPR-A and NPR-B use cyclic guanosine monophosphate (cGMP) as its intracellular messenger. NPR-A binds selectively to ANP and BNP while NPR-B binds selectively to CNP. Although initially thought to have no signaling activity, NPR-C is now believed to inhibit cyclic adenosine monophosphate (cAMP) using the Giα subunit along with activating phospholipase C-β using the Giβγ subunit. The three natriuretic peptides ANP, BNP, and CNP can bind to NPR-C however it has a higher affinity towards ANP and CNP. Natriuretic peptides will lose their activity when degraded by the enzyme neprilysin which is found on the plasma membrane.
Map of Mexican drug war violence Borderland Beat Blog dedicated to reporting on Mexican drug cartels on the border between the US and Mexico Bowers, Charles (2009). "The Mexican Kidnapping Industry". Archived from the original on February 23, 2015. Retrieved April 9, 2009. An academic paper examining both the emergence of kidnapping as a drug war spillover, and statewide variance in Mexico's kidnapping statutes. The Mexican Zetas and Other Private Armies – written by the Strategic Studies Institute. Mexico page on InSight Crime. Ongoing reporting on Mexico's drug war and the involved cartels. "Full Coverage Mexico Under Siege". Los Angeles Times. Archived from the original on April 6, 2014. Retrieved September 12, 2016. The Atlantic: Mexico's Drug War George Grayson, "Mexico's Elite Must Commit to Fighting Drug Cartels", Foreign Policy Association Headline Series. Juarez, City of Death, City of Hope Cocaine Incorporated June 15, 2012 How American guns turned Mexico into a war zone (by Stuart Miller, LA Times, February 24, 2021)
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.